Luye Pharma GroupFRA:LUP +3.03%47 Days Payable is 147.49 as of Dec. 2025, which is 47% above its 10-year median of 100.10. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Luye Pharma Group ranks better than 72.34% on this metric.
The historical rank and industry rank for Luye Pharma Group's Days Payable or its related term are showing as below:
FRA:LUP'
s Days Payable Range Over the Past 10 Years
Min: 45.97 Med: 100.1 Max: 154.74
Current: 141.09
During the past 13 years, Luye Pharma Group's highest Days Payable was 154.74. The lowest was 45.97. And the median was 100.10.
FRA:LUP's Days Payable is ranked better than 72.34% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs FRA:LUP: 141.09
Luye Pharma Group's Days Payable
increased
from Dec. 2024 (131.12) to Dec. 2025 (147.49).
It may suggest that Luye Pharma Groupdelayed paying its suppliers.
Luye Pharma Group Days Payable Related Terms
Luye Pharma Group Days Payable Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Luye Pharma Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Days Payable of 147.49 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Luye Pharma Group and its competitors. This is 47% above median its historical median of 100.10. Over the past decade, Luye Pharma Group's Days Payable has ranged from 45.97 to 154.74. According to the industry distribution chart, Luye Pharma Group ranks #255 out of 922 companies in the Drug Manufacturers industry, placing it in the top 27.7%.
Is Luye Pharma Group's Days Payable too high?
Luye Pharma Group's current Days Payable of 147.49 is 47% above median its 10-year median of 100.10. Over the past 10 years, this metric has ranged from a low of 45.97 to a high of 154.74. The Drug Manufacturers industry median Days Payable is 90.84. Luye Pharma Group's value of 147.49 is 62.4% above this industry median. Based on the distribution chart, Luye Pharma Group ranks #255 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #255 out of 922 companies for Days Payable. This puts Luye Pharma Group in the upper half of its industry. The industry median Days Payable is 90.84. Luye Pharma Group's value of 147.49 is 62.4% above this benchmark. Historically, Luye Pharma Group's own Days Payable has ranged from 45.97 to 154.74 over the past decade. While the company's 10-year median is 100.10 vs. the industry median of 90.84, Luye Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current Days Payable of 147.49 is 62.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current Days Payable is 147.49, which is 47% above median its own 10-year median of 100.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current Days Payable is 147.49, which is 47% above median its 10-year median of 100.10 and 62.4% above the Drug Manufacturers industry median of 90.84. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Days Payable is 147.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Days Payable: 147.49 (47% above median its 10-year median of 100.10)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 62.4% above the Drug Manufacturers median (#255 of 922)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
